Definium Therapeutics, Inc.
DFTX- Exchange
- Nasdaq
- Industry
- Medicinal Chemicals & Botanical Products
- SEC CIK
- 0001813814
In the last 90 days, Definium Therapeutics, Inc. insiders filed 0 open-market purchases and 1 sale; 362 institutions reported holding it in 13F filings for Q2 2026, worth $5.35B in total; Duquesne Family Office is the only superinvestor holding it.
13F holders, Q3 2025
Institutional positions in Definium Therapeutics, Inc. as of Sep 30, 2025. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 196
- +15 vs. Q2 2025
- Shares held
- 39.7M
- −2.05M (−4.9%) vs. Q2 2025
- Total value
- $468.6M
- +$197.6M (+72.9%) vs. Q2 2025
- New holders
- 39
- 56 more added
- Sold out
- 24
- 48 more reduced
2 institutions that held it in Q2 2025 haven't filed for Q3 2025 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting DFTX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 362 | $5.35B |
| Q1 2026 | 248 | $1.47B |
| Q4 2025 | 209 | $908.7M |
| Q3 2025 | 196 | $468.6M |
| Q2 2025 | 183 | $271.0M |
| Q1 2025 | 191 | $240.5M |
| Q4 2024 | 174 | $288.9M |
| Q3 2024 | 158 | $281.6M |
| Q2 2024 | 152 | $299.3M |
| Q1 2024 | 135 | $327.2M |
| Q4 2023 | 104 | $17.9M |
| Q3 2023 | 93 | $12.1M |
| Q2 2023 | 84 | $13.9M |
| Q1 2023 | 89 | $12.6M |
| Q4 2022 | 104 | $11.1M |
| Q3 2022 | 101 | $20.5M |
| Q2 2022 | 156 | $15.1M |
| Q1 2022 | 159 | $53.6M |
| Q4 2021 | 176 | $72.0M |
| Q3 2021 | 175 | $104.8M |
| Q2 2021 | 156 | $131.0M |
| Q1 2021 | 8 | $932.0K |
Institutions, Q3 2025
Shares, value and share of portfolio for each institution holding Definium Therapeutics, Inc.; share changes are against Q2 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Polar Asset Management Partners Inc. | 0 | $0 | 0.00% | −29,300−100.0% | Sold out |
| Mitchell McLeod Pugh & Williams Inc | 0 | $0 | 0.00% | −20,000−100.0% | Sold out |
| Squarepoint Ops LLC | 0 | $0 | 0.00% | −19,684−100.0% | Sold out |
| ExodusPoint Capital Management, LP | 0 | $0 | 0.00% | −17,877−100.0% | Sold out |
| Bailard, Inc. | 0 | $0 | 0.00% | −14,600−100.0% | Sold out |
| Diametric Capital, LP | 0 | $0 | 0.00% | −12,433−100.0% | Sold out |
| PEAK6 LLC | 0 | $0 | 0.00% | −10,915−100.0% | Sold out |
| Sharpepoint LLC | 0 | $0 | 0.00% | −10,165−100.0% | Sold out |
| Capital Advisors Inc | 0 | $0 | 0.00% | −50,000−100.0% | Sold out |
| Clear Street Markets LLC | 0 | $0 | 0.00% | −3,096−100.0% | Sold out |
| Larson Financial Group LLC | 0 | $0 | 0.00% | −2,932−100.0% | Sold out |
| Skopos Labs, Inc. | 0 | $0 | 0.00% | −519−100.0% | Sold out |
| SRS Capital Advisors, Inc. | 0 | $0 | 0.00% | −501−100.0% | Sold out |
| IFP Advisors, Inc | 0 | $0 | 0.00% | 0 | Sold out |
| Caitong International Asset Management Co., Ltd | 0 | $0 | 0.00% | −341−100.0% | Sold out |
| CarsonAllaria Wealth Management, Ltd. | 0 | $0 | 0.00% | −325−100.0% | Sold out |
| Pandora Wealth, Inc. | 0 | $0 | 0.00% | −131−100.0% | Sold out |
| First Pacific Financial | 0 | $0 | 0.00% | −102−100.0% | Sold out |
| TruNorth Capital Management, LLC | 0 | $0 | 0.00% | −33−100.0% | Sold out |
| Total Investment Management Inc | 0 | $0 | 0.00% | −20−100.0% | Sold out |
| Avantax Advisory Services, Inc. | – | – | – | – | Not filed |
| Belmont Capital, LLC | – | – | – | – | Not filed |